Incyte (NASDAQ:INCY) Cut to “Hold” at Wall Street Zen

Posted by George Bondi on Oct 13th, 2026

Wall Street Zen lowered shares of Incyte (NASDAQ:INCY – Free Report) from a buy rating to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Several other brokerages also recently commented on INCY. Leerink Partners raised their target price on Incyte from $131.00 to $155.00 and gave the stock an “outperform” rating in a research note on Monday, August 3rd. Royal Bank Of Canada increased their price target on shares of Incyte from $109.00 to $114.00 and gave the stock a “sector perform” rating in a report on Thursday. Guggenheim raised their price objective on shares of Incyte from $136.00 to $150.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Piper Sandler raised their price objective on shares of Incyte from $110.00 to $130.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. Finally, UBS Group reaffirmed a “neutral” rating and set a $127.00 price objective on shares of Incyte in a research note on Monday, October 5th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and thirteen have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $127.70.

View Our Latest Research Report on INCY

Incyte Price Performance

INCY opened at $111.36 on Friday. The company’s 50-day moving average is $122.61 and its 200 day moving average is $110.34. Incyte has a fifty-two week low of $82.82 and a fifty-two week high of $132.60. The firm has a market capitalization of $22.57 billion, a P/E ratio of 14.19, a PEG ratio of 3.60 and a beta of 0.74.

Incyte (NASDAQ:INCY – Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $3.09 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.94. Incyte had a return on equity of 29.93% and a net margin of 27.71%. The business had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same period last year, the company posted $1.57 earnings per share. Incyte’s quarterly revenue was up 37.7% compared to the same quarter last year. On average, equities research analysts expect that Incyte will post 2.40 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Pablo Cagnoni sold 10,801 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the completion of the transaction, the insider directly owned 183,200 shares of the company’s stock, valued at approximately $23,002,592. This represents a 5.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrick Mayes sold 41,899 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $119.46, for a total value of $5,005,254.54. Following the transaction, the executive vice president directly owned 61,441 shares of the company’s stock, valued at $7,339,741.86. The trade was a 40.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 16.20% of the stock is owned by company insiders.

Institutional Trading of Incyte

A number of hedge funds and other institutional investors have recently modified their holdings of INCY. Fiduciary Financial Advisors bought a new position in Incyte during the 2nd quarter worth $26,000. University of Texas Texas AM Investment Management Co. acquired a new stake in Incyte in the fourth quarter worth $35,000. Continuum Advisory LLC acquired a new stake in Incyte in the second quarter worth $36,000. Quantbot Technologies LP bought a new stake in Incyte in the second quarter valued at $52,000. Finally, Parkside Financial Bank & Trust lifted its stake in Incyte by 49.0% in the second quarter. Parkside Financial Bank & Trust now owns 727 shares of the biopharmaceutical company’s stock valued at $82,000 after buying an additional 239 shares during the last quarter. 96.97% of the stock is owned by hedge funds and other institutional investors.

Incyte Company Profile

(Get Free Report)

Incyte Corporation is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases, with an emphasis on oncology, hematology and inflammatory or dermatologic conditions. The company conducts research through internal programs and collaborations with academic institutions, biotechnology companies and pharmaceutical partners.

Incyte’s marketed portfolio includes Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain myelofibrosis, polycythemia vera and graft-versus-host disease indications, and Opzelura (ruxolitinib) cream for certain inflammatory skin conditions.